James R Berenson, MD
Founder and Chief Scientific Officer
Dr. Berenson is the founder of the Institute for Myeloma & Bone Cancer Research and has specialized in research related to myeloma and metastatic bone disease both in the basic and clinical areas for more than 20 years. He has been involved in many of the major breakthroughs that have brought new treatments for patients with these diseases resulting in both an improvement in the length and quality of their lives.
Dr. Berenson has his private practice in West Hollywood, California, and has specialized in the treatment of patients with multiple myeloma, MGUS, amyloidosis, Waldenstrom’s macroglobulinemia and metastatic bone disease as well as conducting research related to these diseases both in the basic and clinical areas for more than 20 years. He has been involved in many of the major breakthroughs that have brought new treatments for patients with these diseases resulting in both an improvement in the length and quality of their lives.
He serves as a member of the National Institutes of Health – Center for Scientific Review, Clinical Oncology Study Section. He is a member of the Scientific Boards of the Multiple Myeloma Research Foundation and the International Myeloma Foundation. He serves on both the Foundation and the Scientific Boards of the Leukemia, Lymphoma and Myeloma Society. He also works with many other groups known for their work in multiple myeloma and bone metastases.
James Kuo, MD, MBA
Chief Executive Officer
Dr. Kuo has over 20 years of experience in the life science industry as a chief executive officer, business development executive, and venture capitalist. He currently serves as chairman of the board for ImmunoPrecise Antibodies, a publicly-traded biotech company, and chairman of the board for Monarch Labs, a profitable medical device company. Previously, he was chairman and chief executive officer of Synthetic Biologics, a publicly-traded pharma company. While there, two financings and a collaboration with a European pharmaceutical company were completed and the company’s stock went from $0.82 to $2.30.
Dr. Kuo has also been chairman and chief executive officer of BioMicro Systems, a profitable research tools company. The company received several rounds of venture financing, achieved several million dollars in annual sales, and was eventually sold to a major European company. Dr. Kuo has further been chief executive officer of Discovery Laboratories, a publicly-traded company developing surfactant-based respiratory therapeutics.
Earlier in his career, Dr. Kuo was associate director of licensing and development at Pfizer and vice president of business development at Myriad Genetics. He was also managing director of HealthCare Ventures, a $378 million venture capital fund. He received his MD from the University of Pennsylvania School of Medicine and his MBA from the Wharton School of Business. He received his BA in molecular biology from Haverford College.
Thomas J Moss, MD
Chief Medical Officer
Dr. Moss is a board certified Pediatric Hematologist/Oncologist and Transplant specialist trained at UCLA. He has over 25 years of experience in Industry and has been or is CMO/Medical Director for CLIA/GLP Laboratory, Stem Cell company running Phase I and II FDA registration trials, FISH probe manufacturing company, and GMP cell processing company. Dr. Moss is the co-founder of The MT Group, which is a CRO performing translational research studies linked to biologic materials for Pharma. MTG has over 55 sites (hospitals, clinics, and large practices) in 30 states in the US.
Marc D Siegel
Vice President, Business Development
Marc D. Siegel has over 25 years of experience in the healthcare industry. He was co-founder and CEO of BIS Laboratories, a liquid biopsy biotechnology company dedicated to developing novel cancer diagnostics through circulating tumor cell detection and characterization and its relationship to disease recurrence and drug response. BIS was acquired by IMPATH, Inc. where Mr. Siegel was a senior member of the management team responsible for developing IMPATH’s Predictive Oncology group and expanding its CLIA laboratory testing base – resulting in a rapid five-fold increase in revenues. He is a graduate of the Anderson School of Business at UCLA.
Mr. Siegel is a co-founder of The MT Group, a CRO performing translational research studies linked to biologic materials for Pharma. Mr. Siegel is responsible for managing the company’s diverse business activities ranging from biologic materials, diagnostic assay development and commercialization, and general consulting to biopharmaceutical companies in the cancer and stem cell space.
Mr. Siegel also acts as an advisor to companies ranging from nanotechnology and novel molecular and cellular assays to stem cell and cord blood therapeutics and storage. He is a special advisor to companies that license or acquire novel anti-cancer compounds and novel oncology assays. He has served on the advisory board of several therapeutic and diagnostic development companies as well as advised venture capitalists on numerous mergers and acquisitions activities.
Vice President, Quality Management Systems
Steve is a biotechnology professional with extensive experience in in vitro diagnostics, medical device and biopharmaceutical operations and manufacturing environments. Having long tenures at some of the premier companies within the industry (Gen-Probe/Hologic, Chiron/Novartis, Invitrogen/Life Technologies), Steve is uniquely qualified in the areas of manufacturing and quality systems development and implementation, facility design, team building, ISO13485 and cGMP compliance, process validation, equipment qualification and commissioning, manufacturing and quality control management, contract management, project/program management, technology transfer, risk management and design control.
Actively engaged in the assessment, analysis and implementation of productivity, cost reduction and eco-impact improvement projects designed to add value, strength and knowledge for the biotech industry’s operations and manufacturing sectors.
Specialties: Manufacturing management, quality control, product transfer, technology transfer, cGMP, ISO9001, ISO13485, Lean, Six Sigma, High Performance Work Teams, Oligonucleotides, Diagnostics, validation, facility design, project and/or program management, ERP, continuous improvement, outsourcing, third party contract management, design control, and risk management.
Eric received his Bachelor of Science degree in biology from Arizona State University (ASU) in Tempe, AZ. While studying and achieving academic success he swam competitively on their top ten ranked division one team. In 2007 he moved to southern California to continue his professional career in biotechnology and embraced the beach lifestyle by taking up surfing and sailing.
From 2007 to 2018, through several laboratory mergers and acquisitions, he served in various positions of increasing responsibility. He ultimately held the position of laboratory technical supervisor at Covance Inc., a global contract research organization and drug development services company. While managing over a dozen employees Eric supported big pharma drug testing through complex IVD and CDx clinical trials.
Bringing over a decade of industry knowledge in assay validation and laboratory regulation Eric joined OncoTracker as the Laboratory Manager in 2018.
Tahmineh Safaie, MS, DDS
Senior Research Associate
Born in Iran, after being a dentist there for three years, Tahmineh came to the US to start a new career in cancer research. She received her Master of Science from UCLA. Before joining OncoTracker, she was doing research at UCLA Johnson Comprehensive Cancer center studying cancer immunology.
Jessica Yataco, MBA
Jessica received her Bachelor of Science degree in Finance from California State University, Northridge, where she was also a member of the Student Finance Association. Upon graduating, she went on to work for a small home insurance company in Agoura Hills, CA that introduced her to the world of accounting. Her curiosity in this area of the company opened her up to the idea of pursuing work at a company in its mature stage where she could learn various financial strategies as well as expose her to international business topics in order to prepare her for bigger challenges in her career path.
Parsons Corporation, an engineering firm, became that next challenge for 9 years where she held several positions in both accounting and finance. While working as a Finance Manager overseeing forecasts, budgets and daily operations for over 100 engineering projects located all over the United States, Jessica also worked towards earning her MBA from Pepperdine University. Part of her MBA program included Global Enterprise studies at the University of Oxford in England that exposed her to the international environment she was after.
Once Jessica obtained her MBA, she moved to Mexico to lead the accounting department in a Parsons project to build a new international airport in the country’s capital. Having increased her skills in organizational change management by working with international entities as well as various departments (procurement, legal, taxes, HR, and contracts), she moved back to the United States and joined OncoTracker to assist in the development of its business structure.